The present disclosure relates generally to alpha-helix mimetic structures and specifically to alpha-helix mimetic structures that are inhibitors of β-catenin. The disclosure also relates to applications in the treatment of hepatic fibrosis, including hepatic fibrosis associated with hepatitis, hepatic fibrosis associated with hepatitis B infection, and non-alcoholic steatohepatitis (NASH), and pharmaceutical compositions comprising such alpha helix mimetic β-catenin inhibitors.
